ADCC is particularly relevant in the context of therapeutic monoclonal antibodies, such as trastuzumab (for Human Epidermal Growth Factor Receptor-2 (HER2)-positive breast cancer) and rituximab (for B-cell lymphomas) [63,64]. This evidence concerns the gene ERBB2 and B-cell non-Hodgkin lymphoma.